AMN Healthcare Services Inc

AMN remains in a Stage 2 markup within a solid long-term uptrend. Price is consolidating between support and resistance near the short- and mid-term EMAs, with neutral momentum and declining volume arguing for patience before committing. We will defer buying until either a clear breakout above the recent highs is confirmed or a shallow pullback into the rising EMA zone is absorbed, aligning with the High Momentum strategy’s emphasis on shallow retracements into trend continuation.

• ↑Q2 revenue $673M and adjusted EPS $0.77 exceeded guidance; positive earnings revisions.
• ↑Nurse & Allied Solutions revenue $422M, up 11% YoY, shows strong segment demand.
• ↓Negative profitability metrics highlight operational inefficiency and low returns.